JASMINELLECONTINU 0.02 mg/3 mg, film-coated tablet 63 tablets
Active ingredients: Drospirenone, Ethinylestradiol, ÉTHINYLESTRADIOL BÉTADEX-CLATHRATE
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet63 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- JASMINELLECONTINU 0,02 mg/3 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé et comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 3 plaquette(s) PVC-Aluminium de 21 comprimé(s) - 3 plaquette(s) PVC-Aluminium de 7 comprimé(s)
- Marketing authorisation holder
- BAYER HEALTHCARE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 28 Feb 2008
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62251707CIP73764459CIP133400937644594Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉTHINYLESTRADIOLcomprimé actif (rose pâle) | 0,020 mg · un comprimé | FT |
| DROSPIRÉNONEcomprimé actif (rose pâle) | 3 mg · un comprimé | SA |
| ÉTHINYLESTRADIOL BÉTADEX-CLATHRATEcomprimé actif (rose pâle) | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.